Tipo |
Título / Nombre |
Autor(es) |
Año |
|
Dos pacientes mujeres, jóvenes, con fiebre y un mismo destino |
Sigüenza Salgado R, Ibáñez Espacio F, Casas Avilés I, Flores Guerrero A, Bañas Llanos H, Martín Aguilera C, Bermejo Vega N, Arcos Carmona MJ, Martín Mateos M, Prieto Fernández J, Cabrera Silva C, Carnicero F, Bergua Burgués J |
2014 |
|
Azacitidine in older patients with acute Myeloid leukemia (AML) and adverse karyotype. Subanalisis from the Alma Study |
Falantes J, Deben G, Martinez Robles V, Bargay J, Salamero O, Pedro C, Redondo S, Garrido A, Bergua JM, Tormo M, Xicoy B, Font P, González-López TJ, Ramos F |
2014 |
|
Novel assay for ex vivo evaluation of antiproliferative effect of hypomethylating agents 5-Azacytidine and Decitabine in AML patient samples |
Hernández P, Montesinos P, Serrano J, Herrera P, Bergua J, Colorado M, González BJ, Gómez C, Robles A, Gorrochategui J, Sánchez J, Ballesteros J, Moscardo F, Martínez D, Sanz MA, Pérez de Oteyza J, Martínez J |
2014 |
|
A prognostic index for patients with refractory or in first relapsed acute myeloid leukemia treated with FLAG-Ida or Flago-Ida |
Bergua JM, Montesinos P, Martinez-Cuadrón D, Fernández-Abellán P, Serrano J, Sayas MJ, Prieto-Fernández J, García R, García-Huerta AJ, Barrios M, Pérez-López C, Pérez-Encinas M, Siemele A, Rodríguez-Macias G, Herrera-Puente P, Rodríguez-Veiga R, Martínez-Sánchez MP, Amador-Barciela ML, Sanz MA |
2014 |
|
Observational Prospective Registry for the Assessment of the Clinical Impact of Starting Anti-Myeloma Treatment at Biological Relapse |
Alegre A, Gironella M, Bergua JM, González E, Esacalante F, Soler A, Sampol A, González AP, Cabañas V, Lahuerta JJ, López A, Dios A, Bárez A, Ruiz A, Vilanova D, Díaz.Mediavilla J |
2014 |
|
Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA |
Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, Brunet S, Tormo M, Fernández-Abellán P, Guàrdia R, Bernal MT, Esteve J, Barba P, Moreno MJ, Bermúdez A, Cladera A, Escoda L, García-Boyero R, Del Potro E, Bergua J, Amigo ML2, Grand |
2014 |
|
How we should treat the patients with cryptogenic ischemic stroke or transient ischemic attacks and antiphospholipid syndrome? |
Bermejo N, Martín Aguilera C, Bañas H, Arcos MJ, Ibañez F, Salgado R, Casas I, Carnicero F, Bergua J |
2014 |
|
Relevance of parallel use of galactomanann and betaglucan assay in the diagnosis and follow up of fungal infection |
Bergua Burgues JM, Siguenza R, Pazos C, Fernandez-Leyva H, Ibañez F, Prieto J, Martín Mateos ML, Casas I, Bañas H, Cabrera C, Carnicero F, Bermejo-Vega N |
2014 |
|
Acute myeloid leukemia in patients 70 and above. Azacitidine versus intensive chemotherapy |
De La Fuente A, Deben G, Bargay J, Garrido A, Serrano A, Salamero O, Bergua J, Colado E, Garcia R, Pedro C, Redondo S, Tormo M, Bonanad S, Diez-Campelo M, Perez-ncinas M, Xicoy B, Falantes J, Font P, Gonzalez-Lopez T, Martin G, de Oña R, Montesinos P, Ramos F |
2014 |
|
Papel de azacitidina en pacientes con leucemia aguda mieloblástica con cariotipo adverso. Subanálisis del estudio ALMA |
Falantes J.F, Debén G, Martínez-Robles V, Bargay J, Salamero O, Pedro C, Redondo S, Garrido A, Bergua J, Tormo M, Xicoy B, Font P, González-López T.J, Ramos F |
2014 |